Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343–73. https://doi.org/10.1200/JCO.2017.76.6394.

Article  PubMed  Google Scholar 

Parker C, Neville E. Lung cancer * 8: management of malignant mesothelioma. Thorax. 2003;58:809–13. https://doi.org/10.1136/thorax.58.9.809.

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO Classification of Tumours Editorial Board. Thoracic Tumours. Chapter 2: Tumours of the pleura and pericardium. IARC, Lyon; 2021.

Frost G. The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005). Br J Cancer. 2013;109:1965–73. https://doi.org/10.1038/bjc.2013.514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boffetta P, Donato F, Pira E, Luu HN, La Vecchia C. Risk of mesothelioma after cessation of asbestos exposure: A systematic review and meta-regression. Int Arch Occup Environ Health. 2019;92:949–57. https://doi.org/10.1007/s00420-019-01433-4.

Article  PubMed  Google Scholar 

Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, et al. The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. Crit Rev Oncol Hematol. 2016;104:9–20. https://doi.org/10.1016/j.critrevonc.2016.05.004.

Article  CAS  PubMed  Google Scholar 

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1–30. https://doi.org/10.1136/thoraxjnl-2017-211321.

Article  PubMed  Google Scholar 

Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7:543–9. https://doi.org/10.21037/tlcr.2018.07.05.

Article  PubMed  PubMed Central  Google Scholar 

Van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254-307. https://doi.org/10.3978/j.issn.2072-1439.2013.11.28.

Article  PubMed  PubMed Central  Google Scholar 

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5 suppl):v31–9. https://doi.org/10.1093/annonc/mdv199.

Article  PubMed  Google Scholar 

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. https://doi.org/10.1200/JCO.2003.11.136.

Article  CAS  PubMed  Google Scholar 

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402–29. https://doi.org/10.3322/caac.21572.

Article  PubMed  PubMed Central  Google Scholar 

Husain AN, Colby T, Ordonez N, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017;142(1):89–108. https://doi.org/10.5858/arpa.2017-0124-RA.

Article  PubMed  Google Scholar 

Cheng L, Tunariu N, Collins DJ, Blackledge MD, Riddell AM, Leach MO, et al. Response evaluation in mesothelioma: beyond RECIST. Lung Cancer. 2015;90(3):433–41. https://doi.org/10.1016/j.lungcan.2015.08.012.

Article  PubMed  Google Scholar 

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, et al. Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: consensus statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019;14(10):1718–31. https://doi.org/10.1016/j.jtho.2019.08.012.

Article  PubMed  Google Scholar 

Kishimoto T, Fujimoto N, Ebara T, Omori T, Oguri T, Niimi A, et al. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. BMC Cancer. 2019;19(1):1204. https://doi.org/10.1186/s12885-019-6419-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 2014;74:4388–97. https://doi.org/10.1158/0008-5472.CAN-14-1328.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panou V, Røe OD. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. Int J Mol Sci. 2020;21:4327. https://doi.org/10.3390/ijms21124327.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nickell LT Jr, Lichtenberger JP 3rd, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014;34(6):1692–706. https://doi.org/10.1148/rg.346130089.

Article  PubMed  Google Scholar 

Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol. 2018;13(7):1012–21. https://doi.org/10.1016/j.jtho.2018.04.034.

Article  PubMed  Google Scholar 

Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543–9. https://doi.org/10.21037/tlcr.2018.07.05.

Article  PubMed  PubMed Central  Google Scholar 

Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. The IASLC mesothelioma staging project: improving staging of a rare disease through international participation. J Thorac Oncol. 2016;11(12):2082–8. https://doi.org/10.1016/j.jtho.2016.09.123.

Article  PubMed  Google Scholar 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.

Article  PubMed  Google Scholar 

Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma—at the crossroads. JCO Oncol Pract. 2022;18(2):116–24. https://doi.org/10.1200/OP.21.00426.

Article  PubMed  Google Scholar 

Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https://doi.org/10.1183/13993003.00953-2019.

Article  CAS  PubMed  Google Scholar 

Nadal E, Bosch-Barrera J, Cedrés S, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. 2021;23(5):980–7. https://doi.org/10.1007/s12094-020-02532-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sinha S, Swift AJ, Kamil MA, Matthews S, Bull MJ, Fisher P, et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol. 2020;75(6):423–32. https://doi.org/10.1016/j.crad.2019.12.001.

Article  CAS  PubMed  Google Scholar 

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1): e000266. https://doi.org/10.1136/bmjresp-2017-000266.

Article  PubMed  PubMed Central  Google Scholar 

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, et al. The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2089–99. https://doi.org/10.1016/j.jtho.2016.08.147.

Article  PubMed  Google Scholar 

Romei C, Fanni SC, Volpi F, Milazzo A, D’Amore CA, Colligiani L, et al. New updates of the imaging role in diagnosis, staging, and response treatment of malignant pleural mesothelioma. Cancers (Basel). 2021;13(17):4377. https://doi.org/10.3390/cancers13174377.

Article  PubMed  PubMed Central  Google Scholar 

Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol. 2008;43(10):737–44. https://doi.org/10.1097/RLI.0b013e3181817b3d.

Article  PubMed  Google Scholar 

Tsim S, Humphreys CA, Cowell GW, Stobo DB, Noble C, Woodward R, Kelly CA, Alexander L, Foster JE, Dick C, Blyth KG. Early Contrast Enhancement: a novel magnetic resonance imaging biomarker of pleural malignancy. Lung Cancer. 2018;118:48–56. https://doi.org/10.1016/j.lungcan.2018.01.014.

Article  PubMed  Google Scholar 

Elliott HS, Metser U, de Perrot M, Cho J, Bradbury P, Veit-Haibach P, et al. 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. Br J Radiol. 2018;91(1086):20170814. https://doi.org/10.1259/bjr.20170814E.

Article  PubMed  PubMed Central  Google Scholar